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ABSTRACT
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect any organ or system. Neuropsychiatric and 
pulmonary involvement can occur in 40 and 50% of patients respectively, and may occur in several different clinical forms. 
While the main neuropsychiatric manifestations are represented by cognitive impairment, organic cerebral syndromes, 
delirium, psychosis, seizures, and peripheral neuropathies, the main forms of pulmonary involvement are pleurisy with or 
without pleural effusion, pneumonitis, interstitial disease, pulmonary hypertension, and alveolar hemorrhage. The authors 
report the case of a 49-year-old woman whose first manifestation of SLE was represented by two rare manifestations: 
rapidly progressive cognitive impairment, which was associated with respiratory failure caused by the shrinking lung 
syndrome. The authors call attention to the under-diagnosis of lupus pulmonary complications and its association with 
severe cognitive impairment that often necessitates aggressive treatment.
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CASE REPORT
A 49-year-old woman, born and residing in the 
north of Brazil, was brought to medical attention by 
relatives who reported her rapid cognitive decline 
over the last 4 months. According to them, the 
patient had initially presented short-term memory loss 
followed by psychomotor retardation and diminished 
patient-environment interaction, ultimately becoming 
bedridden and fully dependent for basic daily activities. 
A short while after symptom onset, the patient sought 
medical attention and ischemic stroke was diagnosed, 
and she was discharged with the prescription of 
acetylsalicylic acid. She was reportedly alternating 
between periods of partial cognitive recovery and 
the worsening of symptoms. Dyspnea developed and 
worsened over a few weeks until it was present even 
at rest. Her past medical history included hypertension, 
insulin-dependent diabetes mellitus (DM), and 
dyslipidemia. She reported an episode of arthralgia 
(without arthritis) 5 years ago, which improved after 
the use of prednisone for a few months.
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Physical examination showed a pale patient 
with a respiratory rate of 44 breaths per minute; the 
pulse rate was 144 beats per minute; blood pressure 
was 120/90 mmHg, and the axillary temperature 
was 36.4°C. The patient had alopecia without other 
noticeable skin lesions. There was a marked cognitive 
impairment without other neurological findings. The 
remaining examination was normal.
On a previous brain magnetic resonance imaging 
(MRI), there was hyperintense T2 signal on the 
periventricular white matter without signs of ischemia 
or previous strokes (Figure 1).
A chest x-ray (Figure 2) and thoracic computed 
tomography (CT) (Figure 3) revealed the elevation of 
diaphragm domes with minimal pleural effusion, and 
laminar atelectasis consistent with a reduced lung 
volume. Arterial blood gas: pH = 7.47, pO2 = 57 mmHg, 
HCO3 = 20 mEq/L, pCO2 = 28 mmHg, and SpO2 = 87% 
while breathing ambient air. Electrocardiography 
showed sinus tachycardia. The total blood cell count 
showed hemoglobin = 9.4 g/dL (reference value [RV]: 
12.3-15.3 g/dL], leukocytes = 2,930/mm³ (RV: 4.4-11.3 
× 103/mm3) (62% neutrophils, 7% lymphocytes) and 
264,000 platelets/mm3 (RV: 150-400 × 103/mm3). The 
inflammatory markers such as C-reactive protein and 
erythrocyte sedimentation rate were elevated.
Additional laboratory workup revealed: urinalysis 
with proteinuria (1300 mg/24 h (RV: 28-141 mg/24 h) 
wi th normal  ce l l  counts  and without  casts ; 
urea = 35 mg/dL (RV: 5-25 mg/dL); creatinine = 0.46 mg/dL 
(RV: 0.4-1.3 mg/dL); blood glucose = 140 mg/dL (RV: 
70-99 mg/dL); aspartate aminotransferase (AST) = 
29 U/L (RV: 9-36 U/L); and alanine transaminase (ALT) 
= 32 U/L (RV: 10-31 U/L). Kidney ultrasonography 
was consistent with parenchymal disease because 
of the increased echogenicity of the cortex. The 
brain CT showed mild hypodense areas that were 
poorly delimitated at the periventricular white matter 
topography. The cerebral spinal fluid examination 
revealed 2 cells/mm³, 14 red blood cells/mm3, and 
protein of 72.8 mg/dL (RV: < 40 mg/dL). India ink and 
cultures were negative. Serologic tests were negative 
for HIV, syphilis, and hepatitis B and C. Testing for 
cryoglobulins was negative.
Since the patient’s pulse and respiratory rates 
remained elevated over the following days, a 
pulmonary angiotomography was performed, which 
ruled out the diagnosis of pulmonary embolism and 
showed hypoinflated lungs and laminar atelectasis, 
predominantly in the lower lobes. Diaphragm domes 
were elevated, especially at the right side, where, 
along with a tiny pleural effusion, they caused 
partially restrictive atelectasis of the lower and 
Figure 1. Brain MRI exam with hyperintense T2 signal on periventricular white matter.
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Figure 3. Axial thoracic CT revealed reduced lung volume, right tiny pleural effusion and laminar atelectasis. Note 
that no remarkable parenchymal lesion is observed.
Figure 2. Chest X-ray showing reduced lung volume, elevation of diaphragm domes, and laminar atelectasis.
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middle lobes (Figure 3). Normal determination of 
creatine kinase fraction MB (CK-MB), troponin and 
creatine phosphokinase (CPK), an electrocardiogram 
and an echocardiogram ruled out the diagnosis of 
myocarditis. Thyroid hormones were also normal. The 
echocardiogram showed left atrium = 32 mm, ejection 
fraction = 66%, septum = 9 mm, and posterior wall 
= 9 mm. Left and right ventricle sizes were normal. 
The aortic valve was slightly thickened and presented 
a mild reflux. Anemia attributed to a chronic disease 
was confirmed after dosage of iron and vitamin B12.
Antinuclear antibody determination was 1:1280 
showing a nuclear homogeneous pattern and anti-
dsDNA was positive: ELISA > 200 IU/mL (RV: negative 
< 20 UI/mL), confirmed by Crithidia luciliae indirect 
immunofluorescence test. Anti-Sm, anti-Ro (SSA), and 
anti-La (SSB) were negative. (Anti-P, anti-cardiolipin, 
and lupus anticoagulant were not tested.) Complement 
levels were low (C3 = 39 mg/dL [RV: 90-180 mg/dL], 
C4 = 6 mg/dL [RV: 10-40 mg/dL]).
The patient was diagnosed with systemic lupus 
erythematosus (SLE) with pulmonary, hematologic, and 
neuropsychiatric involvement. Renal dysfunction could 
be either attributed to SLE or to the patient’s associated 
conditions (DM and hypertension).
Pulse therapy with methylprednisolone was 
administered (1g/day for 3 days) and the patient 
was started on prednisone (60 mg/day) as well as 
hydroxychloroquine (400 mg/day) afterwards. Her 
cognitive impairment improved remarkably, but she 
still showed signs of psychomotor retardation. The 
respiratory rate improved (26/min without oxygen 
supplementation) and the white blood cells rose to 
normal levels. The patient was discharged and referred 
to a tertiary hospital for outpatient follow-up.
DISCUSSION
Neuropsychiatric and pulmonary involvement 
in SLE has been extensively described, presenting in 
up to 40% and 50% of patients, respectively.1,2 It is 
also known that severe cognitive impairment and the 
shrinking lung syndrome (SLS) are rare manifestations of 
the disease even in patients with both neuropsychiatric 
and pulmonary involvement.
Severa l  forms of  lupus neuropsychiatr ic 
manifestations are observed, which are often associated 
with remarkable morbidity and mortality. Headache, 
humor disorders, anxiety, epilepsy, and cerebrovascular 
disease are the most common syndromes.1,3 High 
titers of anti-phospholipid antibodies, previous or 
current episodes of major neuropsychiatric disorders, 
and elevated systemic activity of the disease are 
considered the main risk factors for the development 
of neuropsychiatric manifestations.1 In this setting, 
syndromes are classified as primary (direct involvement 
of central nervous system [CNS]) or secondary (CNS 
complications related to SLE or its treatment).
Among pr imary  lupus  neuropsych ia t r i c 
manifestations, cognitive impairment has been 
commonly reported (> 5%), while severe or rapidly 
progressive forms are uncommon (3-5%).3 McLaurin 
and colleagues4 reviewed 123 patients with SLE 
in a prospective study, identifying the presence of 
persistently elevated antiphospholipid antibodies, 
diabetes mellitus, depression, lower educational levels, 
and the continuous use of prednisone as the main 
predictors of cognitive impairment.
Mild cognitive disturbances are often subclinical, 
and include a deficit in attention, information processing, 
learning, memory, and executive functions.5,6 These 
diagnoses become evident only with the aid of 
specific neuropsychological tests. Severe and rapidly 
progressive forms are less frequent and can present as 
disorientation, a reduced level of consciousness, and 
hallucinations. These forms seem to be associated with 
generalized involvement of the CNS.5
The physiopathology of neuropsychiatric disorders 
in SLE includes: neuronal and vascular damage secondary 
to intrathecal production of cytokines (interferon alpha, 
interleukins),2,7,8 the rupture of the hematoencephalic 
barrier, and the action of autoantibodies (anti-DNA 
and anti-glutamate-receptor).3 An antiphospholipid 
antibody also play an important role in the cognitive 
impairment of SLE, since it causes direct small vessel 
lesions and microangiopathy, which is often seen 
in imaging studies.6 Neuroimaging findings include 
various degrees of cerebral atrophy, microinfarctions, 
and focal lesions with hyperintensity on T2-weighted 
imaging in white matter.9 However, structural findings 
were nonspecific and none of the neuroimaging 
modalities has shown efficacy in predicting cognitive 
impairment.6
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Secondary causes must always be ruled out in 
rapidly progressive demential processes, including 
medication use, exposure to toxic substances, 
abnormal findings in neurological exam, vitamin B12 
deficiency or thyroid dysfunction.3 Among associated 
medications, corticosteroids seem to be one of the 
main causes of the neuropsychiatric manifestations 
of SLE. Prednisone doses higher than 40mg/day and 
recent therapy are risk factors for the development of 
neuropsychiatric syndromes.10
After excluding secondary causes, treatment 
should be targeted at the presumed etiology of 
cognitive impairment. If it is associated with anti-
phospholipid antibodies, anticoagulation should be 
considered. In the case of antineuronal antibodies, a 
rapid course of corticosteroid (prednisone 0.5 mg/kg 
for a few weeks) can be beneficial.11 Regular use of 
aspirin can prevent cognitive decline in elderly patients.4 
In severe cases, it might be necessary to administer a 
high dose of corticotherapy, immunosuppressive drugs 
(cyclophosphamide, azathioprine), and antipsychotic 
agents. Simultaneously, the patient’s comorbidities 
should always be under control (cardiovascular risk 
factors and, especially, depression). Psycho-educational 
support is recommended for all patients.
The pulmonary involvement in SLE is common 
and includes pleuritis, interstitial lung disease, alveolar 
hemorrhage, thromboembolic disease, pulmonary 
hypertension, airways disease, and SLS.2 The latter is 
considered a rare manifestation of SLE, occurring in 
0.5% of patients and is characterized by unexplained 
dyspnea, episodes of pleuritic chest pain, a progressive 
decrease in lung volumes, a restrictive ventilatory 
defect on pulmonary function tests (PFTs), and no 
evidence of interstitial fibrosis or of significant pleural 
disease on chest CT.2,7,12-14
Dyspnea and restrictive lung disease, apparently 
without pulmonary parenchyma disease, appear 
to be underestimated, since up to 60% of lupus 
patients may have reduced forced vital capacity (FVC) 
in PFT.2,15 Moreover, most of these patients do not 
meet the criteria for SLS diagnosis, which results in 
low prevalence in larger series.16 In an important 
case-control study, Allen and colleagues8 found that 
long-term SLE diagnosis, previous history of pleurisy, 
and positivity for anti–RNP antibodies were associated 
with the diagnosis of SLS. Possible mechanisms 
involved in the pathogenesis of SLS include myopathy 
of respiratory muscles, diaphragmatic paralysis, and 
pulmonary reorganization after several episodes of 
pleural inflammation.7,13,14
Currently, fewer than 100 cases of SLS in adults 
have been reported in the English literature.17 The 
lack of clinical suspicion and the disincentive to report 
milder cases may explain the scarcity of these cases. 
Warrington and colleagues,18 in a comprehensive 
review of literature between 1965 and 1997, found 
49 case reports on SLS. In this review, the mean 
age was 40 years, the patients were predominantly 
females (female: male ratio was 5:1) and there was a 
previous history of pleurisy in almost half the patients 
(45%). A search in the SciELO database revealed 
three case reports of SLS published in the Portuguese 
language,19-21 including one of the articles addressing 
the difficulties of mechanical ventilation in these 
patients during the perioperative care.21 Another 
Brazilian group22 reported a series of four cases with 
an SLS diagnosis, all of whom were females with 
some degree of systemic activity, including lupus 
nephritis. In this series, no patient had neuropsychiatric 
manifestations. The initial manifestation of SLE may be 
represented solely by SLS, challenging the diagnosis of 
SLE as reported by Pillai et al.17
Currently, there is still no consensus on the 
treatment for SLS related to SLE. Most commonly 
recommended therapies involve anti-inflammatories 
and  immunosupp re s s i v e  agen t s . 8 ,22 ,23 O r a l 
corticosteroids are the most used agents, with doses 
ranging from 20 mg/day to 1 mg/kg/day of prednisone. 
In the absence of response to corticosteroids, 
immunosuppressive drugs (cyclophosphamide, 
azathioprine, and methotrexate) or biologic agents 
(rituximab) can be prescribed, with varying reported 
results. Adjuvant treatments with beta-agonists or 
theophylline may be associated as an attempt to 
improve diaphragmatic musculature strength.23
In most patients, dyspnea and thoracic pain 
tend to disappear in days to weeks after treatment.17 
Mortality related to SLS is low; however, full pulmonary 
recovery occurs in only 23% of patients, which runs 
into marked morbidity.24
Pulmonary involvement in the reported case was 
considered as SLS since it presented respiratory distress 
with hypoxemia and reduced lung volumes. Primary or 
secondary pulmonary hypertension was ruled out as 
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both the ECG and the echocardiogram did not show 
right heart dysfunction nor right QRS deviation in the 
horizontal leads. Thoracic angiotomography showed 
no signs of pulmonary embolism, alveolar disease, or 
interstitial lung disease. Neither was there any sign 
of pleural effusion, which could have justified the 
patient’s shortness of breath and elevated respiratory 
rate. Unfortunately PFT was not undertaken due to 
the patient’s impaired mental status. Neurologically, 
the patient presented a severe and rapidly progressive 
cognitive impairment associated with alterations in 
the cerebrospinal fluid, electroencephalogram and 
neuroimaging studies (CT and MRI); consistent with 
CNS lesions caused by immune mediated inflammatory 
process. After pulse corticotherapy, significant 
improvements of cognitive and respiratory functions 
were observed, allowing the continuous treatment 
schedule in the outpatient clinic.
The case reported herein illustrates a concomitance 
of two rare lupus manifestations. The presence of SLS 
is of paramount importance to be diagnosed, since 
proper and early treatment may restore normal lung 
capacity. Similarly, the neuropsychiatric disturbance 
may return to normal with immunosuppressive 
therapy. Although challenging, these manifestations 
should always be suspected when respiratory failure 
ensues without a recognized pulmonary lesion, and 
if dementia-like symptoms arise in a young patient.
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